Autopsy report · NCT04339816

Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomised Controlled Trial

“Steering Committee decision in accordance with stopping rule 1: Emergence of new data”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 6 months before it stopped.
• 3 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Frantisek Duska, MD, PhD

Sponsor type

University, hospital or other

Conditions

COVID-19; Respiratory Failure

Interventions

Azithromycin; Hydroxychloroquine; Placebo

Participants

3

Sites

1

Countries

Czechia

Trials that died the same way

• The Efficacy and Safety of REX-001 to Treat Ischemic Ulcers in Subjects With CLI Rutherford Category 5 and DM
  “Independent Data Monitoring Committee recommendation to stop due to futility” (57% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.